Private companyVertical + EnterpriseGrowth

Insilico Medicine

Insilico Medicine matters because it is one of the most prominent efforts to turn AI for science into a repeatable drug-discovery business.

Hong Kong

Founded

2014

Region

Asia-Pacific

Website

https://insilico.com

Current snapshot

Lifecycle position

Research

New work, prototypes, or early papers.

Preview

Selective access, early demos, or limited pilots.

Growth

Repeatable distribution, partnerships, or ecosystem pull.

Current position

Deployment

Wide production use and durable market presence.

Founded

2014

Watch cadence

Weekly

Last verified

2026-03-31

Focus

AI-first drug discovery and biological research automation

Latest move

Insilico Medicine continues commercializing AI drug-discovery programs and partnerships around its Pharma.AI stack.

Category and subcategory context

Frontier LabsBiotechai-for-sciencescientific-discovery

Competitive context

Isomorphic LabsRecursionGenerate:Biomedicines

Recent models

This profile is tracked more for products and workflow influence than for a standalone model family.

Products

Pharma.AI

Open weights

API access

Watch level

Weekly

Signals

ScienceBiotechScientific discovery

Recent coverage of Insilico Medicine

Recent business and product coverage pulled into the profile so you can see what is happening around the company without leaving the page.

Insilico Medicine caps monumental week at BIO 2026: Secures landmark $2.5B partnership and dominates thought leadership

Insilico Medicine caps monumental week at BIO 2026: Secures landmark $2.5B partnership and dominates thought leadership Insilico Medicine

Insilico Medicine•Jun 30

Human Longevity's Launched New Entity Human Life Foundation Models, Inc. and Insilico Medicine Collaborates to Build the First Foundation Model for Longevity Science

Human Longevity's Launched New Entity Human Life Foundation Models, Inc. and Insilico Medicine Collaborates to Build the First Foundation Model for Longevity Science PR Newswire

PR Newswire•May 27

Insilico Medicine Signs $2.75B AI Drug Discovery Partnership With Eli Lilly

Insilico Medicine Signs $2.75B AI Drug Discovery Partnership With Eli Lilly HLTH

HLTH•Mar 31

Liquid AI and Insilico Medicine Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery

Liquid AI and Insilico Medicine Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery Insilico Medicine

Insilico Medicine•Mar 8

Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery

Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery BioSpace

BioSpace•Mar 3

Liquid AI and Insilico Medicine announce strategic partnership delivering lightweight scientific foundation models for drug discovery

Liquid AI and Insilico Medicine announce strategic partnership delivering lightweight scientific foundation models for drug discovery EurekAlert!

EurekAlert!•Mar 3